Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer’s disease treatment.
About the Author
Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer’s disease treatment.
